case_images: PMC10957540_01
case_images: (A) Immunophenotype of Case 1 from bone marrow flow cytometry. (B) Chemotherapy regimen and therapeutic outcome of Case 1.
case_images: fmed-11-1358161-g001.jpg
case_images: PMC10957540_01_fmed-11-1358161-g001.jpg
case_images: F1
case_images: CD13, CD7, CD117, CD34, CyCD3, and CD2 but not CD4, CD5, CD8, CD3, CD1a, MPO, CD79a, CD33, and CD57 (Figure 1A). Cytogenetics indicated a normal karyotype. Over a 3-year follow-up period, the patient's bone marrow consistently tested negative for MRD (Figure 1B).
case_images: PMC10957540_02
case_images: (A) Immunophenotype of Case 2 from bone marrow flow cytometry. (B) Chemotherapy regimen and therapeutic outcome of Case 2.
case_images: fmed-11-1358161-g002.jpg
case_images: PMC10957540_02_fmed-11-1358161-g002.jpg
case_images: F2
case_images: CD58, CD34, CD7, CD117, CD33, CD13, and CyCD3 but not MPO, CD5, CD2, CD1a, CD4, CD8, and CD3 (Figure 2A). Cytogenetics indicated a normal karyotype and next-generation sequencing indicated mutation in JAK3. Over a 3-year follow-up period, the patient's bone marrow remained negative for MRD (Figure 2B).